Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
94 hedge funds and large institutions have $125M invested in Five Prime Therapeutics, Inc. in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 12 closing their positions.
52% more call options, than puts
Call options by funds: $235K | Put options by funds: $155K
4% less funds holding
Funds holding: 98 → 94 (-4)
25% less capital invested
Capital invested by funds: $167M → $125M (-$41.9M)
27% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 33
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$1.58M |
| 2 |
Barclays
London,
United Kingdom
|
+$955K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$936K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$636K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$553K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.06M |
| 2 |
Millennium Management
New York
|
-$1.32M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$686K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$658K |
| 5 |
SG Americas Securities
New York
|
-$652K |
FPRX Hedge Fund Activity: Q3 2020 in Review
94 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2020, worth a combined $125M — down 25% from $167M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of FPRX and 8 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 24 added.
The largest buyer was Pura Vida Investments, adding an estimated $1.58M. The largest seller was Candriam SCA, exiting entirely with an estimated $3.06M sold.
- 94 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2020, down from 98 in Q2 2020.
- Funds reported $125M of Five Prime Therapeutics, Inc. stock for Q3 2020, down 25% quarter-over-quarter.
- 8 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2020 and 12 closed out, a net change of -4 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2020 was Pura Vida Investments, an estimated $1.58M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2020 was Candriam SCA, an estimated $3.06M sold.
Based on aggregated 13F filings for Q3 2020.